A Andersen1, H Holte, L Slørdal. 1. Section for Clinical Pharmacology, Central Laboratory, The Norwegian Radium Hospital, Box 50, Montebello, 0310 Oslo, Norway. anders.andersen@klinmed.uio.no
Abstract
PURPOSE/ METHODS: Twenty-four patients (17 males and 7 females with a mean age of 54 years) with malignant lymphoma participated in a study of doxorubicin pharmacokinetics after 50 mg/m(2) as 10-min infusions. In addition to plasma samples, serial leukocyte samples and - in one subject - serial biopsy specimens from lymphoma infiltrates were obtained. The samples were analysed by reversed-phase high-performance liquid chromatography. RESULTS: In contrast to several previous studies, the data suggested that 7-deoxydoxorubicinolone, and not doxorubicinone, is a metabolite of doxorubicin in humans. Doxorubicin, but no metabolites, was present in significant and fairly constant concentrations in circulating leukocytes. These levels may reflect the drug levels in lymphoma infiltrates. The data further suggest that metabolism to 7-deoxydoxorubicinone is subject to large interindividual variation, possibly due to a genetic polymorphism, and that significant levels of a metabolic product which may be a doxorubicin glucuronide can be recovered from plasma of patients treated with doxorubicin.
PURPOSE/ METHODS: Twenty-four patients (17 males and 7 females with a mean age of 54 years) with malignant lymphoma participated in a study of doxorubicin pharmacokinetics after 50 mg/m(2) as 10-min infusions. In addition to plasma samples, serial leukocyte samples and - in one subject - serial biopsy specimens from lymphoma infiltrates were obtained. The samples were analysed by reversed-phase high-performance liquid chromatography. RESULTS: In contrast to several previous studies, the data suggested that 7-deoxydoxorubicinolone, and not doxorubicinone, is a metabolite of doxorubicin in humans. Doxorubicin, but no metabolites, was present in significant and fairly constant concentrations in circulating leukocytes. These levels may reflect the drug levels in lymphoma infiltrates. The data further suggest that metabolism to 7-deoxydoxorubicinone is subject to large interindividual variation, possibly due to a genetic polymorphism, and that significant levels of a metabolic product which may be a doxorubicin glucuronide can be recovered from plasma of patients treated with doxorubicin.
Authors: Gabriel A Knudsen; Andrew W Trexler; Alicia C Richards; Samantha M Hall; Michael F Hughes; Linda S Birnbaum Journal: Toxicol Sci Date: 2019-05-01 Impact factor: 4.849
Authors: Andrew T Lucas; Sara K O'Neal; Charlene M Santos; Taylor F White; William C Zamboni Journal: J Pharm Biomed Anal Date: 2015-11-28 Impact factor: 3.935
Authors: Declan McLaughlin; Youyou Zhao; Karla M O'Neill; Kevin S Edgar; Philip D Dunne; Anna M Kearney; David J Grieve; Barbara J McDermott Journal: Br J Pharmacol Date: 2017-04-22 Impact factor: 8.739
Authors: Elisabet Selga; Carlota Oleaga; Sara Ramírez; M Cristina de Almagro; Véronique Noé; Carlos J Ciudad Journal: Genome Med Date: 2009-09-04 Impact factor: 11.117